Clinical trials: Morbus Crohn
Colonic Neoplasms, Crohn Disease
Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy
The primary objective of this study is to retrospectively compare the perioperative and short-term (discharge through 30 days) outcomes of intracorporeal and extracorporeal anastomosis in minimally invasive right colectomies for…
- Trial name
- NCT03019016
- Testing
- Right Colectomy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Intuitive Surgical
Crohn Disease, Remission
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease
The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.
- Trial name
- STATIC (NCT03261206)
- Testing
- 5-ASA Withdrawal
- Where
- 46 sites in Canada, Italy and 2 more
- Volunteers
- 334 people
- Sponsor
- Alimentiv Inc.
Inflammatory Bowel Disease
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
Infliximab (IFX) is highly effective in inducing and maintaining remission in patients with inflammatory bowel disease (IBD). However, a large proportion of patients will eventually lose response to IFX.
- Trial name
- PRECISION (NCT02453776)
- Testing
- PRECISION dosing Infliximab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease
Development of Inflammation and Fibrosis Index, Combining MRI and PET 18F-FDG, in Patient's With Crohn's Disease
Chronic inflammatory bowel disease (IBD) is a disabling, incurable condition that affects 250,000 people in France, and Crohn's disease (CD) is the most common form.
- Trial name
- FILM (NCT04467580)
- Testing
- abdominal [18F]FDG PET/CT
- Volunteers
- 59 people
- Sponsor
- Central Hospital, Nancy, France
Crohn's Disease
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will evaluate the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world…
- Trial name
- CROHNOS (NCT07073079)
- Where
- 25 sites in Italy
- Volunteers
- 250 people
- Sponsor
- AbbVie
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
CD - Crohn's Disease, Stricture; Bowel
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through…
- Conditions
- CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease
- Trial name
- NCT07444060
- Testing
- Guselkumab (GUS), Ustekinumab (UST)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn Disease
Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed…
- Trial name
- NCT01349920
- Testing
- Infliximab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease, Microtia
Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease
In this study, the microbiota sequencing was used to investigate the changes of microbiota in the terminal ileum and the middle part of ascending colon, the mesenteric adipose tissue of ileum and ascending mesocolon, and oral…
- Conditions
- Crohn Disease, Microtia, Ileocecal; Lesion
- Trial name
- NCT05615116
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai 10th People's Hospital
Pediatric Inflammatory Bowel Diseases, Pediatric Crohns Disease
Exercise Training in Youth With Inflammatory Bowel Disease
Children and adolescents with inflammatory bowel disease (IBD) suffer from many extra-intestinal side effects, including impaired muscle strength, low aerobic fitness, low bone density, and chronic inflammation.
- Conditions
- Pediatric Inflammatory Bowel Diseases, Pediatric Crohns Disease, Pediatric Ulcerative Colitis
- Trial name
- NCT05591976
- Testing
- Exercise training program
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- McMaster University
Crohn's Disease
Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)
Hypothesis This study is designed as an integral part of the development of a new CE score for Crohn's disease. The SB (small bowel) CD (Crohn's Disease)Niv score (CECDAI) is an established and validated CD score for SB…
- Trial name
- NCT01793376
- Volunteers
- 30 people
- Sponsor
- Medtronic - MITG
Inflammatory Bowel Diseases
Gallstones and Risk of Inflammatory Bowel Disease
The purpose of this study was to evaluate the association between gallstone disease and the risk of inflammatory bowel disease.
- Trial name
- NCT05882006
- Testing
- gallstones
- Where
- 4 sites in China
- Volunteers
- 5,035 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Crohns Disease
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
- Trial name
- NCT01769755
- Testing
- PDA001
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Celularity Incorporated
Ulcerative Colitis, Crohn's Disease
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).
- Trial name
- NCT02913508
- Testing
- Vedolizumab intravenous injection, Vedolizumab subcutaneous injection
- Sponsor
- Takeda
Ulcerative Colitis (UC), Crohn Disease (CD)
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory…
- Trial name
- NAVIGATE (NCT06606808)
- Testing
- Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Crohn Disease (CD), Colitis Ulcerative
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Inflammatory Bowel Disease (IBD) patients have an increased risk of ColoRectal Cancer (CRC). The cumulative risk of CRC development is estimated at 1% after 10 years of disease progression, 2% after 20 years, and 5% after more…
- Trial name
- IB DYSPLASIA (NCT07719426)
- Volunteers
- 800 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient
Treatment Adherence Among Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy
Inflammatory bowel disease (IBD) is a chronic condition characterized by periods of remission and relapse, requiring long-term treatment adherence to maintain disease control and prevent complications.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient, Structured Education
- Trial name
- NCT07652840
- Testing
- Health Belief Model-Based Structured Patient Education, Standard Patient Education
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Izmir Katip Celebi University
Crohn's Disease, Ulcerative Colitis
Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease
EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD). During the study, patients will participate in an online therapeutic education program.
- Trial name
- EDUMICILOR (NCT03648398)
- Testing
- EDUMICILOR
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Moderately to Severely Active Crohns Disease
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
- Trial name
- SIBERITE-PEDS (NCT07298421)
- Testing
- Afimkibart
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche